AN2 Therapeutics, Inc. business relationships
Companies named in AN2 Therapeutics, Inc.’s 10-K filed 2026-03-17, and public companies whose annual reports name AN2 Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 3 / 100 Top 4% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in AN2 Therapeutics, Inc.’s annual report 3
“Further, we rely upon Anacor's compliance with its license agreement with GSK to maintain our sublicense to such patents owned by GSK, and any termination of Anacor's license agreement with GSK could result in us losing our license to epetraborole.” SEC filing
“...lude melioidosis, a severe bacterial infection associated with high death rates in endemic regions (funded by the U.S. government), and tuberculosis, a leading cause of death from infectious disease worldwide that affects millions of people each year in partnership with the Gates Foundation and GSK.” SEC filing
“License Agreement with Brii Biosciences Limited” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.